Pharma-Bio Serv, Inc.

As of July 31, 2026, Pharma-Bio Serv, Inc. carries a market capitalization of 9.68M, placing it among publicly traded companies globally. Its enterprise value stands at 1.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharma-Bio Serv, Inc.'s next confirmed earnings release is scheduled for February 1, 2027.

As of July 31, 2026, Pharma-Bio Serv, Inc. has 22.90M shares outstanding.

As of July 31, 2026, Pharma-Bio Serv, Inc. trades at a trailing price-to-earnings ratio of 38.47. The price-to-sales ratio is 1.02, and the price-to-book ratio stands at 0.93.

These figures are as of July 31, 2026. The EV/Sales ratio of 0.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.10M versus a market cap of 9.68M, with the gap driven by net debt and cash on the balance sheet.

As of July 31, 2026, Pharma-Bio Serv, Inc. maintains a current ratio of 11.30, meaning it holds 11.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended July 31, 2026, Pharma-Bio Serv, Inc. posted a return on equity (ROE) of 2.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -2.30, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 2.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.24, useful for judging operating efficiency across full business cycles. The company generates approximately 126,448.00 in revenue per employee across its workforce of 75.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended July 31, 2026, Pharma-Bio Serv, Inc. recorded 17,474.00 in income tax expense. That works out to an effective tax rate of 6.50, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 268,999.00, leaving 251,525.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Pharma-Bio Serv, Inc.'s stock has declined approximately 26.23% over the past 52 weeks. The 50-day moving average sits at 0.49, while the 200-day moving average is 0.54.

Over the twelve months ended July 31, 2026, Pharma-Bio Serv, Inc. generated 9.48M in revenue and converted that into 251,525.00 in net income, yielding earnings per share of 0.01. EBITDA reached -24,258.00, while operating income came in at -154,943.00.

These figures are as of July 31, 2026. Total book value stands at 10.44M, with working capital of 10.24M providing operational flexibility.

Pharma-Bio Serv, Inc. produced -414,892.00 in operating cash flow over the twelve months ended July 31, 2026. After subtracting -6,472.00 in capital expenditures, free cash flow totaled -421,364.00 - equivalent to -0.02 per share.

Over the twelve months ended July 31, 2026, Pharma-Bio Serv, Inc. posted a gross margin of 32.32, reflecting its pricing power and cost economics. The operating margin of -1.63 and net profit margin of 2.65 provide insight into operational efficiency.

Over the twelve months ended July 31, 2026, Pharma-Bio Serv, Inc. paid dividends of 0.07 per share. The dividend payout ratio of 682.89 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -4.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 17.87, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pharma-Bio Serv, Inc. shareholders.

As of July 31, 2026, Pharma-Bio Serv, Inc. has an Altman Z-Score of 8.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.